Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02722902
Other study ID # NL56319.068.16
Secondary ID
Status Terminated
Phase N/A
First received February 26, 2016
Last updated April 25, 2018
Start date May 2016
Est. completion date June 2017

Study information

Verified date July 2017
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. To provide more direct insight into the effect of carnitine in preventing metabolic inflexibility and insulin resistance and to further explore the mechanism of action is the focus of this research. Here, we hypothesize that the capacity to form acetylcarnitine may rescue lipid-induced insulin resistance. To this end, insulin resistance will be induced by lipid infusion in healthy volunteers and it will be tested whether carnitine co-infusion can alleviate insulin resistance.


Description:

Rationale: Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. To provide more direct insight into the effect of carnitine in preventing metabolic inflexibility and insulin resistance and to further explore the mechanism of action is the focus of this research. Here, we hypothesize that the capacity to form acetylcarnitine may rescue lipid-induced insulin resistance. To this end, insulin resistance will be induced by lipid infusion in healthy volunteers and it will be tested whether carnitine co-infusion can alleviate insulin resistance.

Objective: The primary objectives are to investigate whether L-carnitine infusion may rescue lipid-induced insulin resistance and whether L-carnitine infusion is improving metabolic flexibility in the state of lipid-induced insulin resistance. Furthermore, a secondary objective is to examine the molecular pathways of carnitine and acetylcarnitine, responsible for muscle insulin sensitivity.

Study design: The current study is an interventional randomized crossover trial in which each subject serves as it owns control. Subjects will be blinded for the intervention.

Study population: n=10, healthy young (18-40 years) male subjects will be included.

Intervention (if applicable): Ten healthy subject will be subjected to the intervention of L-carnitine infusion. To investigate whether L-Carnitine infusion may rescue lipid induced insulin resistance and improve metabolic flexibility three intervention trials are included. The first trial includes lipid infusion combined with L-Carnitine infusion (=LIPID + CAR). In the second trial, L-carnitine infusion will be replaced by placebo infusion in the form of saline (= LIPID + PLAC) in order to investigate the effect of L-Carnitine. During the third trial, lipid infusion will be replaced by infusion of saline and will serve as a control for the lipid infusion (=SALINE + PLAC) and is necessary to investigate to what extend L-carnitine can rescue lipid induced insulin resistance. All three trials will be separated by at least one week. Subjects will be blinded, so no information about the infused substances will be provided to them. The three different trials will be allocated in a random order.

Main study parameters/endpoints: The primary study endpoint is whole body insulin sensitivity, measured by the hyperinsulinemic-euglycemic clamp. Secondary endpoints are maximal acetylcarnitine concentrations after exercise, metabolic compounds in the blood and measurements regarding skeletal muscle metabolism in skeletal muscle tissue obtained by needle biopsies.


Recruitment information / eligibility

Status Terminated
Enrollment 17
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- • Caucasian

- Healthy (as determined by responsible physician based on a medical questionnaire)

- Male

- Age: 18-40 years

- Normal BMI: 18-25 kg/m2

- Stable dietary habits

- No use of medication interfering with investigated study parameters (as determined by responsible physician)

Exclusion Criteria:

- • Female

- Haemoglobin levels < 7.8 mmol/L

- Uncontrolled hypertension

- Use of anticoagulants

- Engagement in exercise > 3 hours a week

- Being vegetarian or vegan (because of altered whole body carnitine status)

- Smoking

- Alcohol and/or drug abuse

- Unstable body weight (weight gain or loss > 5kg in the last 3 months)

- Significant food allergies/intolerances (seriously hampering study meals)

- Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results

- Medication use known to hamper subject's safety during the study procedures

- Medication use known to interfere with investigated study parameters

- Subjects with contra-indications for MRI

- Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study

- Subjects who do not want to be informed about unexpected medical findings

- Subjects who do not want that their treating physician is informed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carnitor
CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes. across the inner mitochondrial membrane.
Dietary Supplement:
IntraLipid
Lipid emulsion for infusion
Placebo
Saline will be used as placebo

Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Whole body insulin sensitivity measured as GIR in µmol/kg/min during the stable period of the insulin phase of the clamp.
Peripheral insulin sensitivity measured as Rd in µmol/kg/min
6 hours
Primary Metabolic flexibility Change in RER comparing basal and insulin stimulated state during the clamp 6-hours
Secondary Maximal acetylcarnitine concentrations after exercise Measured using 1H-MRS after 30 minutes of cycling at 70% Wmax 45 minutes
Secondary glucose concentration in the blood before and during insulin stimulation glucose concentration in the plasma will be measured via a blood draw 6 hours
Secondary Carnitine acyltransferase (CRaT) enzyme activity (physiological parameter) CRaT activity will be measured in obtained muscle biopsies from the vastus Lateralis muscle using enzyme Activity Assays.
Measurements will be obtained using 10 ml of sample incubated in 190 ml reaction buffer (50mM Tris-HCl, 1M EDTA, 0.45mM acetyl-CoA, 0.1mM DTNB; pH = 7.8). CrAT specific activity will be determined by measuring the rate of reduction of DTNB (412 nm) by the free CoA liberated from acetylCoA after adding 5mM L-carnitine and monitoring for 10 min
6 hours
Secondary Acylcarnitine profile in the muscle (physiological parameter) In muscle tissue obtained via biopsies. Acylcarnitine measurements will be performed using flow injection tandem mass spectrometry 6 hours
Secondary Lipid levels (physiological parameter) In muscle tissue obtained via biopsies 6 hours
Secondary free fatty acid in the blood before and during insulin stimulation free fatty acid concentration in the plasma will be measured via a blood draw 6 hours
Secondary Triglycerides in the blood before and during insulin stimulation Triglycerides wil be measured in the plasma via a blood draw 6 hours
Secondary Insulin in the blood before and during insulin stimulation Insulin wil be measured in the plasma via a blood draw 6 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Not yet recruiting NCT01402362 - Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study. N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Completed NCT00740363 - Sitagliptin in Renal Transplant Recipients Phase 4
Completed NCT00436475 - Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Phase 1/Phase 2
Completed NCT04090788 - The Effect of Momordica Charantia Supplementation on Blood Glucose Levels N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Not yet recruiting NCT05462834 - Impact of Nocturnal Hypoxemia on Glucose in High Altitude Sleep Disordered Breathing N/A
Completed NCT03348020 - Iron and Insulin Resistance in Overweight and Obese Humans N/A
Terminated NCT03356873 - Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX) N/A
Completed NCT03922685 - Effects of Diet and Exercise on Circadian Glycemia N/A
Completed NCT03730727 - Exercise-meal Timing and Postprandial Glucose Control N/A
Completed NCT04743960 - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Terminated NCT01887691 - Sleep Effectiveness and Insulin and Glucose Homeostasis Phase 1
Completed NCT02412995 - The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite Phase 0
Not yet recruiting NCT01436448 - Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy Phase 3